pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
GILEAD SCIENCES INC · news · pharmadog
← back to GILEAD SCIENCES INC
News mentioning GILEAD SCIENCES INC
31
stories
12h
STAT+: Three biotechs with three news updates
stat
14h
Supernus, Indivior merger expected to result in ‘natural redundancies’
biospace
15h
STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
stat
1d
STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate case
stat
6d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
7d
Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial
fiercebiotech
8d
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
11d
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
fiercebiotech
11d
Merck stages expanded access to monthly HIV PrEP pill ahead of approval
fiercebiotech
12d
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
12d
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
13d
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
biospace
13d
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
biopharma dive
16d
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
19d
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma
biospace
21d
STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year
stat
22d
STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents
stat
29d
The race for an Ebola therapy begins
stat
Jun 18, 26
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
biopharma dive
Jun 9, 26
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
biopharma dive
Jun 9, 26
Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
endpoints
Jun 9, 26
STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
stat
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 29, 26
Allogene CEO to step down; Agios drug fails key test
biopharma dive
May 29, 26
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
stat
May 28, 26
GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’
biopharma dive
May 22, 26
FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
fda press
May 18, 26
Merck ADC, licensed from China, hits mark in first big global trial
biopharma dive
May 8, 26
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
onclive
May 8, 26
Lilly, Gilead lead pharma’s M&A boom
biopharma dive
← prev
page 1 of 2
next →
